Overactive bladder or non-neurogenic overactive bladder is a syndrome characterized by urinary urgency, frequency, nocturia and urgency incontinence.
It is not a disease but a symptom complex that generally is not a life-threatening condition. It is also known as bladder spasms.
Urgency is the complaint of sudden, compelling desire to pass urine that is difficult to deny. It is considered a hallmark symptom of overactive bladder.
Frequency is usually micturition of >7 episodes during waking hours.
Nocturia is the interruption of sleep one or more times because of the need to void.
Urgency incontinence is the involuntary leakage of urine associated with a sudden compelling desire to void.
Overactive bladder (OAB) is also known as bladder spasms
Defined by the International Continence Society (ICS) as consisting of the following symptoms: urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia, in the absence of causative infection or pathologic conditions, and suggestive of underlying detrusor overactivity (phasic increases in detrusor pressure)
Signs and Symptoms
Complaint of sudden, compelling desire to pass urine which is difficult to defer
Considered as the hallmark of overactive bladder (OAB)
Number of voids and number of incontinence episodes are used to measure treatment responses
Measured using a voiding diary
Number of voiding would vary based on hours of sleep, fluid intake, comorbid medical conditions and other relevant factors
Complaint of interruption of sleep due to the need to void
Urgency urinary incontinence
Involuntary leakage of urine, associated with sudden compelling desire to void
Measured using a diary and by the quantity of urine leakage using pad tests
≥40 years old
Previous pelvic and prostate surgery
Neurological conditions such as diabetic neuropathy, stroke, spinal cord injury, dementia, Parkinson’s disease and multiple sclerosis
Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.